CTI’s Vonjo Shows Potential In Anemic Myelofibrosis Patients, Promising Further Market Growth
Poses Threat To Other JAK Inhibitors
New data from anemic myelofibrosis patients showed the drug reduced transfusion dependence, which that could unlock a more sizeable portion of the market for CTI BioPharma.
You may also be interested in...
The US biotech’s LOXL2 inhibitor candidate has reduced collagen fibrosis of the bone marrow in a small number of Phase II patients, helping validate a historically tricky approach attempted by few.
Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.
The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships.